$14.24
2.01% yesterday
Nasdaq, Dec 03, 10:00 pm CET
ISIN
US29251M1062
Symbol
ENTA

Enanta Pharmaceuticals, Inc. Stock price

$14.24
+3.42 31.61% 1M
+7.05 98.05% 6M
+8.49 147.65% YTD
+5.48 62.56% 1Y
-28.82 66.93% 3Y
-27.62 65.98% 5Y
-15.97 52.86% 10Y
-2.94 17.11% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.28 2.01%
ISIN
US29251M1062
Symbol
ENTA
Industry

Key metrics

Basic
Market capitalization
$411.0m
Enterprise Value
$223.5m
Net debt
positive
Cash
$188.9m
Shares outstanding
21.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.3 | 6.2
EV/Sales
3.4 | 3.3
EV/FCF
negative
P/B
6.4
Financial Health
Equity Ratio
23.1%
Return on Equity
-126.5%
ROCE
-36.8%
ROIC
-141.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$65.3m | $66.7m
EBITDA
$-80.8m | $-98.9m
EBIT
$-85.3m | $-89.1m
Net Income
$-81.9m | $-72.2m
Free Cash Flow
$-32.2m
Growth (TTM | estimate)
Revenue
-3.4% | 2.1%
EBITDA
32.3% | -
EBIT
29.9% | -4.4%
Net Income
29.4% | 11.8%
Free Cash Flow
66.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-123.6% | -148.3%
EBIT
-130.7%
Net
-125.4% | -108.3%
Free Cash Flow
-49.2%
More
EPS
$-3.8
FCF per Share
$-1.5
Short interest
10.2%
Employees
131
Rev per Employee
$500.0k
Show more

Is Enanta Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Enanta Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

Buy
85%
Hold
15%

Financial data from Enanta Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
65 65
3% 3%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 44 44
24% 24%
67%
- Research and Development Expense 107 107
19% 19%
163%
-81 -81
32% 32%
-124%
- Depreciation and Amortization 4.59 4.59
96% 96%
7%
EBIT (Operating Income) EBIT -85 -85
30% 30%
-131%
Net Profit -82 -82
29% 29%
-125%

In millions USD.

Don't miss a Thing! We will send you all news about Enanta Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enanta Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
15 days ago
Enanta Pharmaceuticals (ENTA) remains a "Buy" due to promising secondary endpoints for zelicapavir in RSV, despite missing its primary endpoint. Company's pipeline strength is supported by EDP-323's positive prophylaxis data and robust preclinical immunology programs targeting STAT6 and KIT pathways. The company's strong cash position, now extended into fiscal 2029 after a recent equity raise, ...
Neutral
Business Wire
17 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2025. “This past quarter marked a pivotal period for Enanta, with significant progress across o...
Neutral
Business Wire
about one month ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December. Jefferies London Global Healthcare Conference: Fireside ...
More Enanta Pharmaceuticals, Inc. News

Company Profile

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Luly
Employees 131
Founded 1995
Website www.enanta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today